TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer

<div>Objective response rate (ORR) and disease control rate (DCR) of those treated with TAS-102 monotherapy or combination therapy with bevacizumab for metastatic colorectal cancer.</div>

Gastroenterology Research and Practice

fig3

Figure 3

Figure 3: TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer 